文献速递胃肠外科围术期管理与 ERAS

CDH1基因携带者的腹腔镜预防性全胃切除术联合有限淋巴结清扫

Laparoscopic prophylactic total gastrectomy with limited lymphadenectomy for CDH1 gene carriers.
PubMed 文献 · Surg Endosc · 2023-08-29

单中心回顾性描述性队列研究纳入2012至2022年23例CDH1突变成人患者,行腹腔镜预防性全胃切除术联合D1淋巴结清扫。术后病理显示10例(44%)切除胃标本有胃癌灶,所有淋巴结阴性。作者认为腹腔镜联合有限淋巴结清扫的手术与肿瘤学结局可接受,CDH1携带者可考虑腹腔镜预防性全胃切除术。

要点

  • CDH1突变携带者行腹腔镜预防性全胃切除联合D1淋巴结清扫,所有淋巴结阴性。
  • 术前内镜活检5例(22%)见胃癌灶,切除胃标本10例(44%)见胃癌灶。
  • 作者认为CDH1携带者可考虑腹腔镜预防性全胃切除术。

核心结论

  • 腹腔镜联合有限淋巴结清扫的预防性全胃切除术获得可接受的手术与肿瘤学结局。
  • 尽管无可见癌,超过半数患者切除胃标本存在早期胃癌灶,CDH1携带者可考虑腹腔镜预防性全胃切除术。

研究设计与样本

  • 单中心回顾性描述性队列研究,纳入2012至2022年23例CDH1突变成人患者,均行腹腔镜预防性全胃切除术联合D1淋巴结清扫。
  • 所有患者术前接受食管胃十二指肠镜筛查,筛查见可见肿瘤病灶者被排除且不视为预防性。

主要发现

  • 23例患者中位年龄48岁(IQR 37,53),女性15例(65%),22例(96%)有胃癌和/或小叶乳腺癌家族史。
  • 从基因检测阳性至预防性全胃切除术的中位时间347天(IQR 140,625)。
  • 术前内镜活检5例(22%)见胃癌灶,切除胃标本10例(44%)见胃癌灶,所有淋巴结阴性。
  • 研究期间为处理早期术后并发症,食管空肠吻合技术由EEA改为GIA,且不再放置喂养性空肠造口,术后体重下降变化极小。

临床怎么用

  • 作者认为CDH1携带者可考虑腹腔镜预防性全胃切除术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CDH1 gene mutations are the leading etiology of hereditary diffuse gastric cancer with cumulative lifetime risk ranging up to 83%. Prophylactic total gastrectomy (PTG) is, therefore, recommended for CDH1 carriers. A laparoscopic approach may reduce operative risk versus an open operation, thus leading more patients with CDH1 mutations to pursue PTG prior to cancer development. However, more experience and oncologic outcome data are needed for a laparoscopic approach and indicated lymphadenectomy. METHODS: A retrospective descriptive cohort study of adult patients with CDH1 mutations who underwent laparoscopic PTG with D1 lymphadenectomy between 2012 and 2022 was conducted at a single institution. All patients had preoperative EGD screening, and those with visible tumor lesions on surveillance EGD were excluded and not considered prophylactic. Demographics, family history, pathology, and operative course were obtained. Outcomes included complications, readmission, and postoperative weight change. RESULTS: Among 23 patients, median age was 48 years (IQR 37, 53) and 15 (65%) were female. Family history for gastric and/or lobular breast cancer was present in 22 (96%) patients. The median [IQR] time from positive genetic testing to PTG was 347 days [140, 625]. Pathologic evaluation showed five (22%) patients with foci of gastric cancer on pre-operative EGD biopsies, 10 (44%) in resected stomach specimens. All lymph nodes were negative. To address early postoperative complications, EJ anastomotic technique changed from EEA to GIA over the course of the study and feeding jejunostomy was no longer placed during PTG with minimal change in postoperative weight loss. CONCLUSIONS: This is the largest series, spanning 10 years at a single institution, dedicated solely to a laparoscopic approach for risk-reducing PTG. A laparoscopic approach with limited lymphadenectomy resulted in acceptable surgical and oncologic outcomes. Despite no visible cancer, over half of our patients had foci of early gastric cancer. Therefore, CDH1 carriers should consider laparoscopic PTG.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Bryant MK, Sillcox R, Grady WM, et al. Laparoscopic prophylactic total gastrectomy with limited lymphadenectomy for CDH1 gene carriers. Surg Endosc. 2023. PMID: 37644154. doi:10.1007/s00464-023-10303-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。